cagrilintide phase 2 Updates in Medicine | CagriSema in Adults With or Without Diabetes – REDEFINE 1 & • 💊 2.4 mg + Semaglutide 2.4 mg once weekly • 📉 –20.4% weight News - CagriSema's clinical acceleration

GHK-Cu activates fibroblasts, the cells responsible for collagen and elastin synthesis, and triggers extracellular matrix remodeling through metalloproteinase regulation

I was tired of taking anti-inflammatory meds and exercises that didnt work

Berberine activates AMPK through a different mechanism than MOTS-c (via inhibition of complex I in mitochondria), so concurrent use may create additive rather than synergistic AMPK activationhigher risk of hypoglycemia without proportional metabolic benefit

event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase

Environ Res 161:439445